PDCD1 and sarcoma: The current study provides insights into the immunomodulatory functions of FAP-targeted radiotherapy and demonstrates the therapeutic potential of combining 177Lu-FAP-2287 with an anti-PD-1 monoclonal antibody in a mouse sarcoma model.